Correlation Of Histopahologic Response And Prognostic Markers With Survival In Locally Advanced Non-Small Cell Lung Cancer Patients Who Have Treated With Neoadjuvant Chemotherapy.

e18521 Background: We aimed to determine the response and prognosis in patients with stage III NSCLC who had received neoadjuvant therapy and also to determine the relationship with prognosis and treatment response of the expression of ERCC1 and RRM1. Methods: 27 patients with stage III NSCLC were included in this study who received neoadjuvant chemotherapy and had been operated between 2003 and 2013. Lung tissue biopsies were evaluated by immunohistochemical methods for ERCC1 protein expression in patients who received neoadjuvant cisplatin and for RRM1 protein expression in patients who received neoadjuvant gemcitabine. Results: 1 (3.7%) women and 26 (96.3%) male patients were enrolled in the study. Median age was 59 (45-75). 14 patients (51.9%) underwent lobectomy and 13 patients (48.1%) were performed pneumonectomy. 19 patients (70.4%) were at stage 3A and eight patients (29.6 %) were at stage 3B. 13 patients (48.1%) received adjuvant cisplatin-based chemotherapy. 3 patients (11.1%) received postoperative radiotherapy. The median follow-up time was 36 months. In all patients, the average DFS was 26.6 months. The average OS was 48 months. From the perspective of stage 3A and 3B; DFS (p = 0.379) and OS (p = 0.69) did not differ significantly in terms. 16 patients (59.3%) after receiving neoadjuvant chemotherapy was found viable tumor ratio equal and under 10% in the surgical pathology materials. 11 patients (40%) was found viable tumor above the rate of 10% . When considered from this point of view DFS (p = 0.16) and OS (p = 0.097) showed no difference. The DFS (p = 0.846) and OS (p = 0.6) was not different between patients who received adjuvant chemotherapy and who did not. Conclusions: In patients with stage III NSCLC who received neoadjuvant chemotherapy found longer OS and DFS durations than from literature. ERCC1 and RRM1 expressions that were predictive markers of response of the treatment for cisplatin and gemcitabine was not correlated to therapy and survival.